Shire to Buy Eye-Drug Maker SARcode for $160 Million

Shire Plc, a maker of medicines for rare genetic diseases, agreed to buy closely held SARcode Bioscience Inc. for at least $160 million to expand in drugs for eye conditions.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.